Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Open-label, Multicenter Phase 3 Study to Assess the Efficacy and Safety of GIVinostat Versus Hydroxyurea IN JAK2V617F-positive High-risk Polycythemia Vera Patients: the GIV-IN PV TRIAL

NCT06093672 is registered in ClinicalTrials.gov with Italfarmaco as lead sponsor.

NCT NCT06093672
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06093672 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Open-label, Multicenter Phase 3 Study to Assess the Efficacy and Safety of GIVinostat Versus Hydroxyurea IN JAK2V617F-positive High-risk Polycythemia Vera Patients: the GIV-IN PV TRIAL
Lead sponsor
Italfarmaco
Phase
Phase 3
Overall status
Recruiting
Start date
March 26, 2024
Completion date
July 31, 2026
Enrollment
220 (estimated)
Sites
90

Conditions

As the registry lists them; a condition with its own page is linked.

polycythemia vera